For Immediate Release
Chicago, IL – August 22, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include St. Jude Medical, Inc. (STJ), Medtronic (MDT), Boston Scientific (BSX), Washington Federal Inc. (WAFD) and CIT Group Inc. (CIT).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Tuesday’s Analyst Blog:
St. Jude's Riata Woes Continue
Recently, the U.S. Food and Drug Administration (:FDA) agency instructed medical devices major, St. Jude Medical, Inc. (STJ) to conduct a study to examine insulation failure in Riata defibrillator leads, a thin wire used to connect cardiac resynchronization therapy defibrillator (CRT-D) or implantable cardioverter defibrillator (:ICD) to the heart to monitor abnormal heart rhythm.
The agency has recommended that X-rays or other imaging alternatives should be conducted in patients who have been implanted with the heart device to increase clinical know-how. The FDA also recommended St. Jude to carry out post-market surveillance studies to accumulate information regarding the risks associated with the Riata leads for 3 years.
The FDA had issued, in late 2011, an urgent recall of the Riata and Riata ST leads given the potential risk of serious injury or patient death. St. Jude had stopped selling the product in 2010. As of 2011, about 79,000 U.S. citizens had been implanted with these leads.
Although the FDA believes that most of the leads are harmless, despite signs of electrical conductor migration or externalization, it is still necessary to collect data on the frequency and timing of insulation failure to advance medical treatment and enhance patient safety.
The FDA’s scrutiny is supported by a number of studies which have indicated that a regular checkup may identify more problems that remained undetected earlier. However, the FDA has also cautioned health care professionals not to remove the leads randomly, without properly evaluating the condition of the patient.
Earlier, St. Jude had announced early phase-one results from its Riata Lead Evaluation Study. It was found that externalized conductors occurred less frequently in Riata ST 7F with a small diameter in comparison to the thicker Riata 8F leads. Management asserted that the results were consistent with other published studies. The company’s Leads Medical Advisory Board did not make any changes to existing patient management recommendations.
Apart from the post-market studies for Riata and Riata ST ICD and CRT-D leads, the FDA has asked St. Jude to conduct post-market surveillance studies on its QuickFlex LV CRT leads, QuickSite LV CRT leads and Riata ST Optim and Durata ICD leads. In April 2012, St. Jude had voluntarily recalled its QuickFlex LV CRT leads and the QuickSite LV CRT leads due to insulation abrasion.
If such a trend continues and similar product recalls follow in the future, it will negatively impact the company’s goodwill and might act as leverage for its peers such as Medtronic (MDT) and Boston Scientific (BSX) to gain market share. Moreover, we remain cautious about the restructuring expenses within the CRM business as well as the overall weakness in the CRM market. We currently have a Neutral recommendation on St. Jude, along with a short-term Zacks #4 Rank (Sell).
WAFD Restructures Balance Sheet
Washington Federal Inc. (WAFD) has announced the sale of securities and repayment of its long-term debt. The company has decided to restructure its balance sheet is an effort to mitigate the effects of interest rate risk and improve earnings.
Over the last 10 days, to reduce interest rate risk Washington Federal sold $2.4 billion worth of fixed rate mortgage backed securities for a pre-tax gain of $95 million. These securities yielded 3.22% (on annualized basis) in July. Further, the company pre-paid $876 million of costly long-term debt (weighted average rate of 3.94%) at a pre-tax loss of $95 million.
Nevertheless, Washington Federal also bought certain assets - short as well as long term - worth $1.7 billion, having an average weighted yield of 1.85%. Moreover, the company increased the maturity period of an additional $100 million of long-term debt to bring down the weighted average rate to 3.33% from 4.04%.
Similar to Washington Federal, CIT Group Inc. (CIT) has been constantly restructuring its balance sheet to bring down its cost of capital and improve profitability. CIT announced that it would redeem $681 million of its 7% Series C Notes maturing in 2016 on September 17. With the completion of this redemption, the company would have redeemed or refinanced approximately $31 billion of high-cost long-term debt since 2010.
The ongoing macro economic conditions and low interest rate environment prompted Washington Federal to restructure its balance sheet and enhance capital ratios. This will lower the interest expense burden and fuel net interest income growth. These restructuring initiatives will also assist in fencing margin pressure and provide more financial flexibility.
Management anticipates similar actions to continue in the future. We believe all these initiatives to favor growth going forward.
Washington Federal currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Considering the fundamentals, we also maintain a long-term ‘Neutral’ recommendation on the stock.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339
More From Zacks.com